GlaxoSmithKline Gets Closer to Vir Biotechnology with Pan-Coronavirus Collaboration and Equity Investment
Posted on 04/06/2020
Vir Biotechnology, Inc., which is a listed company backed with some sovereign wealth fund capital, signed a binding agreement with GlaxoSmithKline plc (the units – GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA) to collaborate on researching and developing solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. GlaxoSmithKline views Vir’s proprietary monoclonal […]
